Description
ADCC-Enhanced anti-STEAP-1 (120.545) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
Prostate Cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced STEAP-1 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
STEAP1
Full Name
six transmembrane epithelial antigen of the prostate 1
Background
This gene is predominantly expressed in prostate tissue, and is found to be upregulated in multiple cancer cell lines. The gene product is predicted to be a six-transmembrane protein, and was shown to be a cell surface antigen significantly expressed at cell-cell junctions.
Alternative Names
STEAP1; six transmembrane epithelial antigen of the prostate 1; STEAP; PRSS24; metalloreductase STEAP1; six-transmembrane epithelial antigen of prostate 1
Gene ID
26872
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG2aκ
Antibody Clone
120.545
Description
The monoclonal antibody against to six-transmembrane epithelial antigen of the prostate-1 (STEAP-1) can inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo.
Antibody Indication
Prostate Cancer
